Lilianna Suarez1, Asheley C Skinner2,3, Tracy Truong4, Jessica R McCann5, John F Rawls5, Patrick C Seed6, Sarah C Armstrong7,3. 1. Duke University School of Medicine, Durham, NC, USA. 2. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. 3. Duke Clinical Research Institute, Duke University, Durham, NC, USA. 4. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA. 5. Department of Molecular Genetics and Microbiology, Duke Microbiome Center, Duke University School of Medicine, Durham, NC, USA. 6. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Abstract
Background: Treatment options for adolescents with obesity are limited. Yet, therapies previously reserved for adults, such as medications and bariatric surgery, are increasingly available to adolescents in tertiary obesity treatment settings. We aimed to identify the factors associated with selecting an advanced obesity treatment (diets, medications, and surgery) beyond lifestyle therapy among adolescents presenting to a tertiary, pediatric weight management program. Methods: We conducted a secondary analysis of adolescents (N = 220) who participated in a longitudinal, observational case-control study within a pediatric weight management program. The exposures were potential individual and clinical factors, including sociodemographic characteristics and comorbidities. The outcome was treatment selection, dichotomized into lifestyle vs. advanced treatment. We modeled associations between these factors and treatment selection using logistic regression, controlling for confounding variables (age, race/ethnicity, sex, and insurance). Results: The study population included a majority of non-Hispanic Black (50.5%) and Hispanic/Latino (19.5%) adolescents, of whom 25.5% selected advanced treatment. Adolescents were more likely to choose an advanced treatment option if they had a greater BMI [odds ratio (OR) 1.09, 95% confidence interval (95% CI) 1.04-1.15], lived further from the clinic (OR 1.03, 95% CI 1.00-1.05), and had an elevated glycohemoglobin level (OR 2.46, 95% CI 1.24-4.92). Conclusions: A significant fraction of adolescents seeking obesity treatment in a specialized care setting chose new and emerging obesity treatments, particularly those at high risk of developing diabetes. These findings can inform patient-clinician obesity treatment discussions in specialty care settings. Clinical Trial Registration number: NCT03139877.
Background: Treatment options for adolescents with obesity are limited. Yet, therapies previously reserved for adults, such as medications and bariatric surgery, are increasingly available to adolescents in tertiary obesity treatment settings. We aimed to identify the factors associated with selecting an advanced obesity treatment (diets, medications, and surgery) beyond lifestyle therapy among adolescents presenting to a tertiary, pediatric weight management program. Methods: We conducted a secondary analysis of adolescents (N = 220) who participated in a longitudinal, observational case-control study within a pediatric weight management program. The exposures were potential individual and clinical factors, including sociodemographic characteristics and comorbidities. The outcome was treatment selection, dichotomized into lifestyle vs. advanced treatment. We modeled associations between these factors and treatment selection using logistic regression, controlling for confounding variables (age, race/ethnicity, sex, and insurance). Results: The study population included a majority of non-Hispanic Black (50.5%) and Hispanic/Latino (19.5%) adolescents, of whom 25.5% selected advanced treatment. Adolescents were more likely to choose an advanced treatment option if they had a greater BMI [odds ratio (OR) 1.09, 95% confidence interval (95% CI) 1.04-1.15], lived further from the clinic (OR 1.03, 95% CI 1.00-1.05), and had an elevated glycohemoglobin level (OR 2.46, 95% CI 1.24-4.92). Conclusions: A significant fraction of adolescents seeking obesity treatment in a specialized care setting chose new and emerging obesity treatments, particularly those at high risk of developing diabetes. These findings can inform patient-clinician obesity treatment discussions in specialty care settings. Clinical Trial Registration number: NCT03139877.
Entities:
Keywords:
adolescents; bariatric surgery; drug treatment
Authors: Heena P Santry; Diane S Lauderdale; Kathleen A Cagney; Paul J Rathouz; John C Alverdy; Marshall H Chin Journal: Ann Surg Date: 2007-01 Impact factor: 12.969
Authors: Asheley Cockrell Skinner; Sophie N Ravanbakht; Joseph A Skelton; Eliana M Perrin; Sarah C Armstrong Journal: Pediatrics Date: 2018-03 Impact factor: 7.124
Authors: Jaime Moore; Matthew Haemer; Nazrat Mirza; Ying Z Weatherall; Joan Han; Caren Mangarelli; Mary Jane Hawkins; Stavra Xanthakos; Robert Siegel Journal: Int J Environ Res Public Health Date: 2019-05-20 Impact factor: 3.390
Authors: Elizabeth A O'Connor; Corinne V Evans; Brittany U Burda; Emily S Walsh; Michelle Eder; Paula Lozano Journal: JAMA Date: 2017-06-20 Impact factor: 56.272